Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting

Recruiting

• Conditions: Cirrhosis
• Interventions: Procedure: Rectus abdominis muscle biopsy

• Registration Number: NCT03121404
• Lead Sponsor: The Cleveland Clinic

Brief Summary

Cirrhosis is characterized by loss of muscle as well as fat mass, which increases morbidity and mortality before, during, and after liver transplantation. A common mechanism for the reduced muscle and fat mass in cirrhosis is an increased expression of the TGF (transforming growth factor)beta superfamily member, myostatin, in the muscle and adipose tissue. The present study will examine the expression of myostatin, its receptor and intracellular signaling pathways in the skeletal muscle and mesenteric adipose tissue in cirrhotic patients undergoing liver transplantation as compared to healthy controls undergoing planned abdominal surgery. 16 cirrhotic patients will be identified from the transplant list, and 16 healthy controls from outpatient surgery lists. Nutritional assessment will be performed, including anthropometry (triceps skinfold thickness, mid arm circumference), dual energy x-ray absorptiometry (DEXA), and bioelectrical impedance analysis (BIA). Rectus abdominis muscle tissue and omental fat tissue will be harvested in the operating room, and the expression of signaling proteins involved in skeletal muscle protein synthesis will be quantified. The investigator will also quantify the expression of genes involved in lipolysis and lipid synthesis. The investigator anticipates that the expression of myostatin will be higher in the skeletal muscle and adipose tissue of cirrhotics as compared to controls. There will be a reduction in the expression of the signaling proteins that regulate skeletal muscle protein synthesis, as well as the expression of genes regulating lipogenesis. The increased expression of myostatin will also correlate with reduced anthropometric and DEXA measurements of lean body mass and fat mass.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11-14
• Study First Submitted: 2017-04-12
• Study First Submitted QC: 2017-04-17
• Study First Posted: 2017-04-20
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-12
• Last Update Posted: 2025-03-13
• Primary Completion: 2025-12-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Age 18-70 years
• Patients undergoing abdominal surgery (liver transplantation or other surgery)

Control

1. non liver transplant donor
2. Elective abdominal surgery (cholecystectomy, diverticulosis, acute gastrointestinal bleeding in the absence of exclusion criteria)

Exclusion Criteria

• Exclusion criteria (all subjects)
• Average daily alcohol intake > 20 g in women and > 30 g in men
• Diabetes or a fasting serum glucose > 100 mg/dL
• Hyper- / hypo- thyroidism
• Renal disease with serum creatinine > 1.4 mg/dL
• Folate or vitamin B12 deficiency
• Active intravenous drug use
• History of bowel surgery or gastric bypass surgery
• Medications/supplements that affect fat mass or protein mass (creatine, glucocorticoids)
• Pregnancy
• Chronic diseases that result in cachexia (renal, cardiac, pulmonary, hematologic, cancer)
• Hepatocellular cancer

Exclusion criteria (controls)

• Evidence of malnutrition as quantified by triceps skinfold thickness, mid arm muscle area and creatinine height index)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Healthy Controls	Rectus abdominis muscle biopsy	Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
Cirrhosis Patient	Rectus abdominis muscle biopsy	Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).

Primary Outcome Measures

Name	Time	Method
Determine the difference in myostatin expression between healthy control and cirrhosis patients	15 minute biopsy	The primary outcome of this study is to determine the difference in expression of myostatin in skeletal muscle in a one time biopsy of the Rectus abdominis muscle between healthy controls and cirrhotic patients.

Trial Locations

Locations (1)

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States